Premium
Experimental treatment of chronic Trypanosoma cruzi infection in mice with 2‐ n ‐propylquinoline
Author(s) -
Nakayama Hector,
Ferreira Maria Elena,
Arias Antonieta Rojas de,
Bilbao Ninfa Vera de,
Torres Susana,
Schinini Alicia,
Fournet Alain
Publication year - 2001
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.877
Subject(s) - benznidazole , trypanosoma cruzi , chagas disease , serology , nifurtimox , medicine , drug , kinetoplastida , trypanosomiasis , pharmacology , biology , immunology , parasite hosting , antibody , world wide web , computer science
It was reported previously that 2‐ n ‐propylquinoline was active against the epimastigote form of Trypanosoma cruzi . The effects of oral treatments with benznidazole and 2‐ n ‐propylquinoline were evaluated in Balb/c mice infected with T. cruzi chronically. The reference drug and 2‐ n ‐propylquinoline were administered 60 days post‐infection for 30 days at 25 mg/mL. At 35 days post‐treatment, the serological tests (ELISA) of the 2‐ n ‐ propylquinoline‐treated mice were significantly different from the controls ( p = 0.01) and the benznidazole‐treated mice ( p = 0.03), while this was not the case at 85 days post‐treatment. These results are encouraging for continuing the investigation of other analogues of 2‐ n ‐propylquinoline in experimental chronic Chagas' disease. Copyright © 2001 John Wiley & Sons, Ltd.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom